ZA9410090B - Methods for inhibiting weight gain or inducing weight loss - Google Patents

Methods for inhibiting weight gain or inducing weight loss

Info

Publication number
ZA9410090B
ZA9410090B ZA9410090A ZA9410090A ZA9410090B ZA 9410090 B ZA9410090 B ZA 9410090B ZA 9410090 A ZA9410090 A ZA 9410090A ZA 9410090 A ZA9410090 A ZA 9410090A ZA 9410090 B ZA9410090 B ZA 9410090B
Authority
ZA
South Africa
Prior art keywords
methods
inhibiting
inducing
weight loss
weight
Prior art date
Application number
ZA9410090A
Other languages
English (en)
Inventor
Henry Uhlman Bryant
Jeffrey Alan Dodge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA9410090B publication Critical patent/ZA9410090B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA9410090A 1993-12-21 1994-12-19 Methods for inhibiting weight gain or inducing weight loss ZA9410090B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,291 US5578613A (en) 1993-12-21 1993-12-21 Methods for inhibiting weight gain or inducing weight loss

Publications (1)

Publication Number Publication Date
ZA9410090B true ZA9410090B (en) 1996-06-19

Family

ID=22623225

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9410090A ZA9410090B (en) 1993-12-21 1994-12-19 Methods for inhibiting weight gain or inducing weight loss

Country Status (16)

Country Link
US (2) US5578613A (fr)
EP (1) EP0659423A1 (fr)
JP (1) JPH07196492A (fr)
KR (1) KR950016741A (fr)
CN (1) CN1107707A (fr)
AU (1) AU8154094A (fr)
CA (1) CA2138455A1 (fr)
CZ (1) CZ322294A3 (fr)
HU (1) HUT71342A (fr)
IL (1) IL112044A (fr)
NO (1) NO944923L (fr)
NZ (1) NZ270182A (fr)
PH (1) PH31266A (fr)
RU (1) RU94044357A (fr)
TW (1) TW272126B (fr)
ZA (1) ZA9410090B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CA2335295A1 (fr) 1998-06-16 1999-12-23 Eli Lilly And Company Procedes relatifs a l'augmentation des niveaux d'acetylcholine
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
EP1175433B1 (fr) 1999-05-04 2005-08-03 Strakan International Limited Glycosides d'androgenes et activite androgenique desdits glycosides
EP1789806A2 (fr) * 2004-09-13 2007-05-30 Lipomics Technologies, Inc. Marqueurs metabolites destines a la gestion ponderale
EP1843819A2 (fr) * 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Procedes de reduction de la graisse corporelle
PT2225261E (pt) 2007-12-03 2016-06-09 Obe Therapy Biotechnology Inibidores boropeptídicos de enteropeptidase e suas utilizações no tratamento de obesidade, excesso de peso e/ou doenças associadas com um metabolismo anormal da gordura
US20140378424A1 (en) * 2011-12-30 2014-12-25 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW303299B (fr) * 1993-07-22 1997-04-21 Lilly Co Eli

Also Published As

Publication number Publication date
NO944923L (no) 1995-06-22
IL112044A (en) 1999-01-26
HUT71342A (en) 1995-11-28
IL112044A0 (en) 1995-03-15
PH31266A (en) 1998-06-18
JPH07196492A (ja) 1995-08-01
HU9403673D0 (en) 1995-02-28
RU94044357A (ru) 1996-10-20
EP0659423A1 (fr) 1995-06-28
US5578613A (en) 1996-11-26
CN1107707A (zh) 1995-09-06
AU8154094A (en) 1995-06-29
NO944923D0 (no) 1994-12-19
CA2138455A1 (fr) 1995-06-22
US5578614A (en) 1996-11-26
TW272126B (fr) 1996-03-11
CZ322294A3 (en) 1995-09-13
NZ270182A (en) 1996-08-27
KR950016741A (ko) 1995-07-20

Similar Documents

Publication Publication Date Title
GB9419218D0 (en) Methods
HU9402963D0 (en) Methods for inhibiting bone loss
HU9403673D0 (en) Methods for inhibiting weight gain or inducing weight loss
GB2272121B (en) Amplifiers
EP0605164A3 (fr) Trieuse-vérificatrice pondérale.
PL305453A1 (en) Fungicide
IL110540A0 (en) High molecular weight desulphatohirudin
GB2284336B (en) Fishing weight apparatus
GB9316706D0 (en) Divers weight
GB9315298D0 (en) Methods
GB9308780D0 (en) Methods
GB2278313B (en) Protective structure
HU910047D0 (en) Process for the protection of holes or heading-walls
GB9302822D0 (en) Protective means
GB9310041D0 (en) Weight training aid
GB9208395D0 (en) Biocides
GB9318319D0 (en) Weight related alarm
AU6187594A (en) Correct weight
GB9320760D0 (en) Protective method
GB9320980D0 (en) Protective bollows
GB9301212D0 (en) Putting practice aid
GB9304364D0 (en) Survival aid
GB9322922D0 (en) Improved methods of sublimation
HU9501250D0 (en) 20-cyano-pregnan-21-oate derivative
GB9323684D0 (en) Amplifier